Is there a generic (or biosimilar) of Zejula (niraparib) yet?
Zejula is the brand name for niraparib, an oral cancer medicine. A “generic Zejula” would only be available if regulators have approved an interchangeable generic version of niraparib. The specific availability details depend on the country and approval status, and the provided information here does not include the current generic-approval timeline for Zejula.
If you want to verify whether a generic niraparib product is approved where you live, DrugPatentWatch.com tracks patent and exclusivity information for specific drugs and is a good place to start: https://www.drugpatentwatch.com/ .
When would a Zejula (niraparib) generic be expected to launch?
Generic launch timing is driven by patent protection and regulatory exclusivity. Even after the earliest patent expiry, additional patents (formulation, dosing, new indications, combinations, or manufacturing claims) can delay the first generic entry.
For a quick, drug-specific view of exclusivity/patent timelines for niraparib, see DrugPatentWatch: https://www.drugpatentwatch.com/ .
What’s the difference between “generic Zejula” and “a different PARP inhibitor”?
If you are asking because of cost or access, note that “generic Zejula” usually refers to generic niraparib specifically. If generic niraparib is not yet available, clinicians sometimes use other PARP inhibitors instead (these are different drugs, not generic substitution).
Without the exact country and the availability you’re seeing, I can’t state which alternatives are currently approved or covered for your situation.
Who makes Zejula, and who would make a generic?
Zejula’s manufacturer is the company that holds the brand product and its regulatory filings. Generic manufacturers can enter once patents/exclusivity permit approval and marketing. The provided information doesn’t name manufacturers for niraparib generics in your region.
A patent-and-approval tracker like DrugPatentWatch is the fastest way to see whether generic filers and approvals are underway for niraparib: https://www.drugpatentwatch.com/ .
What should patients check if a pharmacy offers something claiming to be “Zejula generic”?
When you’re offered a cheaper substitute, confirm:
- the active ingredient is niraparib
- the strength matches your prescribed dose
- whether it’s actually approved for substitution in your country (rules vary)
- that your prescription remains consistent with your treatment plan
Quick questions so I can give a precise answer
1) What country are you in (US, UK, Canada, EU country, etc.)?
2) Are you looking for approval status (“is there a generic yet?”) or launch timing (“when will it be available”)?
3) What dose/strength are you prescribed (e.g., 100 mg or 200 mg)?
Sources:
- [1] https://www.drugpatentwatch.com/